Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Immunome Single Cell Profiling Reveals T Cell Exhaustion with Upregulation of Checkpoint Inhibitors LAG3 and Tigit on Marrow Infiltrating T Lymphocytes in Daratumumab and IMiDs Resistant Patients

Paola Neri, MD, Ranjan Maity, PhD, Ines Tagoug, PhD, Sylvia McCulloch, MD, Peter Duggan, MD, Victor Jimenez-Zepeda, MD, Jason Tay, MD, Anjan Thakurta, PhD, Nizar Bahlis, MD

Blood (2018) 132 (Supplement 1): 242.

https://doi.org/10.1182/blood-2018-99-117531

Published: 2018

Journal Articles

Single Cell Analysis of Acquired Pomalidomide-Resistance in Multiple Myeloma Cell Lines Reveals Distinct Subclonal Cereblon Mutations and Gene Expression Heterogeneity

Sarah Gooding, Chad C. Bjorklund, Michael Amatangelo, Yan Ren, Mathieu Marella, Suzana Couto, Christopher Park, Sneh Lata, Reshma Nibhani, Fadi Towfic, PhD, Udo Oppermann, Karthik Ramasamy, William E. Pierceall, Paresh Vyas, Anjan Thakurta, PhD

Blood (2018) 132 (Supplement 1): 2648.

https://doi.org/10.1182/blood-2018-99-112644

Published: 2018

Journal Articles

Chromothripsis and Chromoplexy Are Associated with DNA Instability and Adverse Clinical Outcome in Multiple Myeloma

Blood (2018) 132 (Supplement 1): 408.

https://doi.org/10.1182/blood-2018-99-117359

Published: 2018

Journal Articles

Cyclophosphamide Exerts Significant Immunomodulatory Function in Myeloma Patients Treated with Pomalidomide and Dexamethasone

James Croft, BSc, MBBS, MRCP, Andrew Hall, Katrina Walker, Amy L Sherborne, PhD, Kevin Boyd, Mamta Garg, Charlotte Pawlyn, BA, PhD MBBChir, MRCP, FRCPath, Debbie Sherratt, Sadie Reed, PhD, William E Pierceall, Gordon Cook, Anjan Thakurta, PhD, Sarah R Brown, PhD MSc, BSc, Martin Kaiser, MD

Blood (2018) 132 (Supplement 1): 4482.

https://doi.org/10.1182/blood-2018-99-111823

Published: 2018

Journal Articles

Hotspot Mutations in SF3B1 Result in Increased Alternative Splicing in Multiple Myeloma and Activation of Key Cellular Pathways

Michael A Bauer, PhD, Cody Ashby, PhD, Christopher Wardell, PhD, Maria Ortiz, Erin Flynt, Anjan Thakurta, PhD, Gareth Morgan, MD, Brian A Walker, PhD

Blood (2018) 132 (Supplement 1): 4454.

https://doi.org/10.1182/blood-2018-99-116858

Published: 2018

Journal Articles

Long-Term Follow-up Identifies Double Hit and Key Mutations As Impacting Progression Free and Overall Survival in Multiple Myeloma

Cody Ashby, PhD, Eileen Boyle, Ruslana G. Tytarenko, MS, Hongwei Wang, MS, Adam Rosenthal, MS, Purvi Patel, Yan Wang, Shayu Deshpande, Maria Ortiz, Erin Flynt, Antje Hoering, PhD, Sharmilan Thanendrarajan, MD, Carolina D. Schinke, MD, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Bart Barlogie, MD PhD, Anjan Thakurta, PhD, Gareth Morgan, MD, Brian A Walker, PhD

Blood (2018) 132 (Supplement 1): 110.

https://doi.org/10.1182/blood-2018-99-113045

Published: 2018

Journal Articles

Modeling Tumor Microenvironment Interactions of Imid Sensitive and Resistant Cells in 3D Organotypic Culture Models

Aarif Ahsan, PhD, Danny Jeyaraju, Kamlesh Bisht, Patrick R. Hagner, PhD, Chad C. Bjorklund, William E Pierceall, Anjan Thakurta, PhD

Blood (2018) 132 (Supplement 1): 5622.

https://doi.org/10.1182/blood-2018-99-118885

Published: 2018

Journal Articles

Landscape of Recurrent Mutations in Non-Coding Genome with Functional Implications in Newly-Diagnosed Multiple Myeloma

Mehmet Kemal Samur, PhD, Chandraditya Chakraborty, PhD, Raphael Szalat, MD, Anil Aktas Samur, PhD, Mariateresa Fulciniti, PhD, Michael A Lopez, Masood A. Shammas, PhD, Paul Richardson, Florence Magrangeas, PhD, Stephane Minvielle, PhD, Philippe Moreau, Michel Attal, Anjan Thakurta, PhD, Kenneth Anderson, MD, Giovanni Parmigiani, Hervé Avet-Loiseau, MDPhD, Nikhil Munshi, MD

Blood (2018) 132 (Supplement 1): 190.

https://doi.org/10.1182/blood-2018-190

Published: 2018

Journal Articles

Immune Profiling of Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide and Low-Dose Dexamethasone in Combination with Daratumumab

Blood (2018) 132 (Supplement 1): 2012.

https://doi.org/10.1182/blood-2018-99-111554

Published: 2018

Journal Articles

Mechanistic Insights of Pomalidomide Activity in Combination with Bortezomib and Dexamethasone in Multiple Myeloma and Immune Cells

Mark Katz, Chad C. Bjorklund, Anjan Thakurta, PhD, Natalya Serbina

Blood (2018) 132 (Supplement 1): 1934.

https://doi.org/10.1182/blood-2018-99-118829

Published: 2018

Journal Articles

Iberdomide (CC-220) Has Synergistic Anti-Tumor and Immunostimulatory Activity Against Multiple Myeloma in Combination with Both Bortezomib and Dexamethasone, or in Combination with Daratumumab in Vitro

Michael Amatangelo, Chad C. Bjorklund, Jian Kang, Ann Polonskaia, Sridevi Viswanatha, Anjan Thakurta, PhD

Blood (2018) 132 (Supplement 1): 1935.

https://doi.org/10.1182/blood-2018-99-113383

Published: 2018

Journal Articles

A High-Risk Multiple Myeloma Group Identified By Integrative Multi-Omics Segmentation of Newly Diagnosed Patients

Maria Ortiz, Fadi Towfic, PhD, Mehmet Kemal Samur, PhD, Erin Flynt, In Sock Jang, PhD, Kai Wang, PhD, Cody Ashby, PhD, Brian A Walker, PhD, Matthew Trotter, PhD, Gareth Morgan, MD, Nikhil Munshi, MD, Anjan Thakurta, PhD

Blood (2018) 132 (Supplement 1): 3165.

https://doi.org/10.1182/blood-2018-99-117114

Published: 2018

Journal Articles

Clonal Heterogeneity in Differentiation Response and Resistance to the IDH2 Inhibitor Enasidenib in Acute Myeloid Leukemia

Blood (2017) 130 (Supplement 1): 724.

https://doi.org/10.1182/blood.V130.Suppl_1.724.724

Published: 2017

Journal Articles

MYC Rearrangements in Multiple Myeloma Are Complex, Can Involve More Than Five Different Chromosomes, and Correlate with Increased Expression of MYC and a Distinct Downstream Gene Expression Pattern

Aneta Mikulasova, PhD, Cody Cody Ashby, PhD, Ruslana G. Tytarenko, MS, Michael Bauer, PhD, Konstantimos Mavrommatis, PhD, Christopher P. Wardell, PhD, Matthew Trotter, PhD, Shayu Deshpande, Owen W. Stephens, Erming Tian, PhD MBA, Graham Jackson, Faith E. Davies, MD, Anjan Thakurta, PhD, Nikhil Munshi, MD, Gareth J. Morgan, MD PhD, Brian A Walker, PhD

Blood (2017) 130 (Supplement 1): 65.

https://doi.org/10.1182/blood.V130.Suppl_1.65.65

Published: 2017

Journal Articles

Correlative Analyses of Cereblon ( CRBN ), cMYC , IRF4 , BLIMP1 , and XBP1 with Clinical Outcomes in Stratus (MM-010), a Phase 3b Study of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Xiaozhong Qian, Meletios A. Dimopoulos, Michael Amatangelo, PhD, Chad Bjorklund, Katja C. Weisel, Enrique M. Ocio, MDPhD, Xin Yu, Teresa Peluso, Lars Sternas, Mohamed Zaki, Philippe Moreau, MDPhD, Anjan Thakurta, PhD

Blood (2017) 130 (Supplement 1): 3109.

https://doi.org/10.1182/blood.V130.Suppl_1.3109.3109

Published: 2017

Journal Articles

Higher Expression of Nuclear Cereblon in Bone Marrow Biopsies of Patients with Multiple Myeloma Included in the HOVON-87/Nmsg-18 Trial May be Associated with Longer PFS and OS

Ruth Wester, King Hong Lam, MD PhD, Mark van Duin, PhD, Suzana Couto, Yan Ren, Maria Wang, PhD, Bronno van der Holt, Berna Beverloo, PhD, Heleen Visser-Wisselaar, Alex Nigg, Max Qian, Anjan Thakurta, PhD, Annemiek Broyl, MD PhD, Sonja Zweegman, MD PhD, Pieter Sonneveld, MDPhD

Blood (2017) 130 (Supplement 1): 3052.

https://doi.org/10.1182/blood.V130.Suppl_1.3052.3052

Published: 2017

Journal Articles

Crowdsourcing a High-Risk Classifier for Multiple Myeloma Patients

Blood (2017) 130 (Supplement 1): 265.

https://doi.org/10.1182/blood.V130.Suppl_1.265.265

Published: 2017

Journal Articles

Safety and Efficacy of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) As Second- or Third-Line Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) after Lenalidomide (LEN)-Based Treatment (Tx) Failure

Blood (2017) 130 (Supplement 1): 1811.

https://doi.org/10.1182/blood.V130.Suppl_1.1811.1811

Published: 2017

Journal Articles

Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) Safety and Efficacy in Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Previously Treated with a Proteasome Inhibitor (PI) and in Whom Last Prior Therapy with Lenalidomide (LEN) Failed

David Siegel, MD PhD, Gary J. Schiller, MD, Kevin W Song, MD, Richy Agajanian, Ketih Stockerl-Goldstein, Hakan Kaya, Michael Sebag, MD PhD, Christy Samaras, Ehsan Malek, MD, Giampaolo Talamo, Christopher S. Seet, Jorge Mouro, MS, Faiza Zafar, MPAS, Weiyuan Chung, Shankar Srinivasan, PhD, Max Qian, Amit Agarwal, MD PhD, Anjan Thakurta, PhD, Nizar J. Bahlis, MD

Blood (2017) 130 (Supplement 1): 1812.

https://doi.org/10.1182/blood.V130.Suppl_1.1812.1812

Published: 2017

Journal Articles

Immune Profile of Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) in the Second Line Immediately after Lenalidomide (LEN)

Blood (2017) 130 (Supplement 1): 1888.

https://doi.org/10.1182/blood.V130.Suppl_1.1888.1888

Published: 2017

NARROW

Immunome Single Cell Profiling Reveals T Cell Exhaustion with Upregulation of Checkpoint Inhibitors LAG3 and Tigit on Marrow Infiltrating T Lymphocytes in Daratumumab and IMiDs Resistant Patients

Single Cell Analysis of Acquired Pomalidomide-Resistance in Multiple Myeloma Cell Lines Reveals Distinct Subclonal Cereblon Mutations and Gene Expression Heterogeneity

Chromothripsis and Chromoplexy Are Associated with DNA Instability and Adverse Clinical Outcome in Multiple Myeloma

Cyclophosphamide Exerts Significant Immunomodulatory Function in Myeloma Patients Treated with Pomalidomide and Dexamethasone

Hotspot Mutations in SF3B1 Result in Increased Alternative Splicing in Multiple Myeloma and Activation of Key Cellular Pathways

Long-Term Follow-up Identifies Double Hit and Key Mutations As Impacting Progression Free and Overall Survival in Multiple Myeloma

Modeling Tumor Microenvironment Interactions of Imid Sensitive and Resistant Cells in 3D Organotypic Culture Models

Landscape of Recurrent Mutations in Non-Coding Genome with Functional Implications in Newly-Diagnosed Multiple Myeloma

Immune Profiling of Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide and Low-Dose Dexamethasone in Combination with Daratumumab

Mechanistic Insights of Pomalidomide Activity in Combination with Bortezomib and Dexamethasone in Multiple Myeloma and Immune Cells

Iberdomide (CC-220) Has Synergistic Anti-Tumor and Immunostimulatory Activity Against Multiple Myeloma in Combination with Both Bortezomib and Dexamethasone, or in Combination with Daratumumab in Vitro

A High-Risk Multiple Myeloma Group Identified By Integrative Multi-Omics Segmentation of Newly Diagnosed Patients

Clonal Heterogeneity in Differentiation Response and Resistance to the IDH2 Inhibitor Enasidenib in Acute Myeloid Leukemia

MYC Rearrangements in Multiple Myeloma Are Complex, Can Involve More Than Five Different Chromosomes, and Correlate with Increased Expression of MYC and a Distinct Downstream Gene Expression Pattern

Correlative Analyses of Cereblon ( CRBN ), cMYC , IRF4 , BLIMP1 , and XBP1 with Clinical Outcomes in Stratus (MM-010), a Phase 3b Study of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Higher Expression of Nuclear Cereblon in Bone Marrow Biopsies of Patients with Multiple Myeloma Included in the HOVON-87/Nmsg-18 Trial May be Associated with Longer PFS and OS

Crowdsourcing a High-Risk Classifier for Multiple Myeloma Patients

Safety and Efficacy of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) As Second- or Third-Line Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) after Lenalidomide (LEN)-Based Treatment (Tx) Failure

Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) Safety and Efficacy in Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Previously Treated with a Proteasome Inhibitor (PI) and in Whom Last Prior Therapy with Lenalidomide (LEN) Failed

Immune Profile of Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) in the Second Line Immediately after Lenalidomide (LEN)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only